Management of Advanced HIV with Multiple Opportunistic Infections and IRIS

Initial Assessment and Stabilization

Evaluate CD4 count and viral load to determine degree of immunosuppression in patients with advanced HIV infection, typically with CD4 count <100 cells/μL, according to the Infectious Diseases Society of America 1, 2
Perform lumbar puncture to diagnose cryptococcal meningitis, measuring opening pressure and obtaining CSF for cryptococcal antigen, India ink, and culture, as recommended by the Infectious Diseases Society of America 3, 4
Obtain sputum samples for tuberculosis testing, including GeneXpert MTB/RIF, acid-fast bacilli smear, and culture, and PJP PCR, as suggested by the American Thoracic Society 5, 2
Consider urine TB-LAM testing for rapid TB diagnosis in patients with CD4 <100 cells/μL, according to the American Thoracic Society 6
Initiate supplemental oxygen for hypoxemia and stabilize hemodynamics before starting specific antimicrobial therapy, as recommended by the Infectious Diseases Society of America 1

Begin induction therapy with amphotericin B deoxycholate (0.7-1 mg/kg/day IV) plus flucytosine (100 mg/kg/day orally in 4 divided doses) for 2 weeks, as recommended by the Infectious Diseases Society of America 3, 4
Follow with consolidation therapy using fluconazole 400-800 mg/day for 8 weeks, and continue with maintenance therapy using fluconazole 200 mg/day until immune reconstitution (CD4 >100 cells/μL for at least 3 months), according to the Infectious Diseases Society of America 3, 4
Manage increased intracranial pressure with serial lumbar punctures to maintain CSF pressure <20 cm H₂O, as suggested by the Infectious Diseases Society of America 3, 4

Initiate four-drug antitubercular therapy with isoniazid (300 mg/day), rifampin (600 mg/day), pyrazinamide (15-30 mg/kg/day), and ethambutol (15-25 mg/kg/day), as recommended by the American Thoracic Society 5
Continue treatment for at least 9-12 months in patients with TB meningitis or disseminated disease, according to the American Thoracic Society 5
Monitor for hepatotoxicity with regular liver function tests, especially when combined with other potentially hepatotoxic drugs, as suggested by the American Thoracic Society 5

Administer trimethoprim-sulfamethoxazole (TMP-SMX) at 15-20 mg/kg/day of TMP component in 3-4 divided doses for 21 days, as recommended by the Infectious Diseases Society of America 1, 2
For patients with moderate to severe PJP (PaO₂ <70 mmHg or A-a gradient >35 mmHg), add prednisone at 40 mg twice daily for 5 days, then 40 mg daily for 5 days, followed by 20 mg daily for 11 days, according to the Infectious Diseases Society of America 1

For patients with cryptococcal meningitis, defer ART initiation until 4-6 weeks after starting antifungal therapy to reduce risk of IRIS, as recommended by the National Institutes of Health 8
For patients with TB and CD4 <50 cells/μL without meningitis, start ART within 2 weeks of TB treatment, according to the World Health Organization 8, 6
For patients with TB and CD4 >50 cells/μL without meningitis, start ART within 2-8 weeks of TB treatment, as suggested by the World Health Organization 8, 6

Prefer dolutegravir-based regimens due to high barrier to resistance and fewer drug interactions, as recommended by the National Institutes of Health 8
When using rifampin, double the dose of dolutegravir to 50 mg twice daily, according to the National Institutes of Health 8
Avoid efavirenz with bedaquiline (if used for drug-resistant TB) due to drug interactions, as suggested by the American Thoracic Society 6

For severe IRIS manifestations (CNS inflammation, respiratory decompensation), administer corticosteroids (prednisone 0.5-1.0 mg/kg/day or dexamethasone for severe CNS symptoms) for 2-6 weeks with gradual taper, as recommended by the Infectious Diseases Society of America 4
Continue antimicrobial therapy and ART during IRIS treatment, according to the Infectious Diseases Society of America 4
For TB-IRIS, prednisone has been shown to reduce morbidity and the need for hospitalization, as suggested by the American Thoracic Society 5, 6

Continue PJP prophylaxis with TMP-SMX until CD4 >200 cells/μL for at least 3 months, as recommended by the Infectious Diseases Society of America 1, 2
Continue cryptococcal maintenance therapy until CD4 >100 cells/μL for at least 3 months, according to the Infectious Diseases Society of America 3, 4
Consider TB preventive therapy for contacts after active TB is treated, as suggested by the American Thoracic Society 5

Monitor CD4 count and HIV viral load every 3 months, as recommended by the National Institutes of Health 8
Perform regular clinical assessments for treatment response and drug toxicities, according to the Infectious Diseases Society of America 1
For cryptococcal meningitis, repeat lumbar puncture after 2 weeks of therapy to document CSF sterilization, as suggested by the Infectious Diseases Society of America 3
Assess adherence to all medications at each visit, according to the National Institutes of Health 1, 8